文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

成人脐带血移植与匹配相关供者移植的总生存相当且无GVHD无复发生存更优

Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.
PubMed 文献 · Blood Adv · 2020-01-01

本研究比较了本中心2010至2017年间接受外周血干细胞移植的成人匹配相关供者(MRD)患者与接受双份脐带血移植(CBT)的成人患者结局,共190例CBT与123例MRD。全队列CBT的总体生存(OS)与MRD相当(P=.61),而无GVHD无复发生存(GRFS)显著优于MRD(P=.0056),主要因CBT后中重度慢性GVHD减少(P<.0001;HR 3.99;95%CI 2.26-7.04)。作者结论支持CBT的疗效,并提示对能耐受较强预处理且复发风险高的患者,脐带血可能是首选供者来源。

要点

  • 全队列CBT的OS与MRD相当(P=.61),GRFS显著优于MRD(P=.0056)。
  • CBT后中重度慢性GVHD减少(P<.0001;HR 3.99;95%CI 2.26-7.04)。
  • 常用清髓方案中CBT的GRFS显著更优(P=.006),OS相当(P=.136)。

核心结论

  • 本中心结果支持CBT的疗效,并提示对能耐受较强预处理且复发风险高的患者,脐带血可能是首选供者来源。

研究设计与样本

  • 本中心2010至2017年间成人双份脐带血移植(CBT)190例与成人匹配相关供者外周血干细胞移植(MRD)123例的结局比较。

主要发现

  • 全队列CBT与MRD的OS相当(P=.61),GRFS在CBT显著改善(P=.0056),主要因CBT后中重度慢性GVHD减少(P<.0001;HR 3.99;95%CI 2.26-7.04)。
  • 常用清髓方案中CBT与MRD的OS相当(P=.136),GRFS在CBT显著改善(P=.006)。
  • 常用清髓方案中CBT组复发累积发生率呈下降趋势(P=.075;HR 1.85;95%CI 0.94-3.67),移植相关死亡(TRM)相当(P=.55;HR 0.75;95%CI 0.29-1.95)。
  • 常用非清髓方案中CBT与MRD的OS和GRFS均相当(P=.158和P=.697)。
  • 常用非清髓方案中CBT与MRD的复发累积发生率(P=.32;HR 1.35;95%CI 0.75-2.5)和TRM(P=.14;HR 0.482;95%CI 0.18-1.23)均相当。

临床怎么用

  • 作者认为,对能耐受较强预处理且复发风险高的患者,脐带血可能是首选供者来源。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We compared outcomes among adult matched related donor (MRD) patients undergoing peripheral blood stem cell transplantation and adult patients undergoing double unit cord blood transplantation (CBT) at our center between 2010 and 2017. A total of 190 CBT patients were compared with 123 MRD patients. Median follow-up was 896 days (range, 169-3350) among surviving CBT patients and 1262 days (range, 249-3327) among surviving MRD patients. Comparing all CBT with all MRD patients, overall survival (OS) was comparable (P = .61) and graft-versus-host disease (GVHD) relapse-free survival (GRFS) was significantly improved among CBT patients (P = .0056), primarily because of decreased moderate to severe chronic GVHD following CBT (P < .0001; hazard ratio [HR], 3.99; 95% confidence interval [CI], 2.26-7.04). Among patients undergoing our most commonly used MRD and umbilical cord blood (CB) myeloablative regimens, OS was comparable (P = .136) and GRFS was significantly improved among CBT patients (P = .006). Cumulative incidence of relapse trended toward decreased in the CBT group (P = .075; HR, 1.85; CI 0.94-3.67), whereas transplant-related mortality (TRM) was comparable (P = .55; HR, 0.75; CI, 0.29-1.95). Among patients undergoing our most commonly used nonmyeloablative regimens, OS and GRFS were comparable (P = .158 and P = .697). Cumulative incidence of both relapse and TRM were comparable (P = .32; HR, 1.35; CI, 0.75-2.5 for relapse and P = .14; HR, 0.482; CI, 0.18-1.23 for TRM). Our outcomes support the efficacy of CBT and suggest that among patients able to tolerate more intensive conditioning regimens at high risk for relapse, CB may be the preferred donor source.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sharma P, Purev E, Haverkos B, et al. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020. PMID: 32442301. doi:10.1182/bloodadvances.2020001554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。